400 related articles for article (PubMed ID: 31020569)
21. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
22. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y; Zhang YN; Wang KT; Chen L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib: A Review in Hepatocellular Carcinoma.
Heo YA; Syed YY
Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
[TBL] [Abstract][Full Text] [Related]
26. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
da Fonseca LG; Reig M; Bruix J
Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
[TBL] [Abstract][Full Text] [Related]
30. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
31. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Atsukawa M; Itobayashi E; Tsuji K; Tajiri K; Hirooka M; Shimada N; Shibata H; Ishikawa T; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Itokawa N; Imai M; Joko K; Hiasa Y; Michitaka K;
Cancer Med; 2019 Jan; 8(1):137-146. PubMed ID: 30575325
[TBL] [Abstract][Full Text] [Related]
32. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Parikh ND; Singal AG; Hutton DW
Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
[TBL] [Abstract][Full Text] [Related]
34. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
[TBL] [Abstract][Full Text] [Related]
35. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
36. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
38. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
39. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
40. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]